Terodiline, emepronium bromide or placebo for treatment of female detrusor overactivity? A randomised, double-blind, cross-over study.
In a randomised, double-blind study, 20 women with idiopathic detrusor instability and associated symptoms were treated with terodiline 25 mg bd, placebo, and emepronium bromide 200 mg tds--each drug being given for 3 weeks with placebo as wash-out period before cross-over. The results were evaluated according to drug preference, frequency charts and elimination of detrusor instability on cystometry. Serum levels of both drugs were monitored as control of tablet intake. The preference for terodiline to placebo was statistically significant: 14/3 women (P less than 0.05), and the majority of women (12/4) preferred terodiline to emepronium. Terodiline also gave a small but significant reduction in 24 h micturition frequency and eliminated detrusor instability in almost 50% of the patients (P less than 0.05). Side effects were frequent but mild in all three treatment periods. It was concluded that terodiline offers an alternative in the treatment of female detrusor instability.
Andersen
J R
JR
Department of Surgery K, Frederiksberg Hospital, Copenhagen, Denmark.
Lose
G
G
Nørgaard
M
M
Stimpel
H
H
Andersen
J T
JT
D000328:Adult; D000368:Aged; D002082:Butylamines / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004629:Emepronium / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D011897:Random Allocation; D001745:Urinary Bladder Diseases / Q000188:drug therapy*
D002082:Butylamines; D002121:Calcium Channel Blockers; D000644:Quaternary Ammonium Compounds; D004629:Emepronium; C010637:terodiline